Bridgeway Capital Management, LLC Affimed N.V. Transaction History

Bridgeway Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$1.58 - $4.63 $67,782 - $198,627	-42,900 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $470,016 - $985,728	-326,400 Reduced 88.38%	42,900 $68,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $3.07 $255,375 - $348,445	113,500 Added 44.37%	369,300 $1.01 Million
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $682,986 - $933,670	255,800 New	255,800 $752,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.